OncoMatch/Clinical Trials/NCT07311408
SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure
Is NCT07311408 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including SHR-1701+Rivoceranib + SHR-2554 and SHR-1701 + Rivoceranib for gastric cancer (gc).
Treatment: SHR-1701+Rivoceranib + SHR-2554 · SHR-1701 + Rivoceranib — To investigate the efficacy of SHR-1701 combined with Rivoceranib, with or without SHR-2554, in patients with gastric or gastroesophageal junction adenocarcinoma who have progressed on or were intolerant to first-line immunotherapy-containing treatment
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Esophageal Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Required: HER2 (ERBB2) negative expression (negative)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: checkpoint inhibitor
Disease progression on or intolerance to a prior treatment regimen that contained an immune checkpoint inhibitor (ICI)
Cannot have received: investigational agent
Treatment with any other investigational agent within 4 weeks prior to the first dose of the study drug, or within 5 half-lives of the previous investigational agent (whichever is longer)
Cannot have received: antitumor therapy
Any antitumor therapy (including radiotherapy, chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biotherapy, or tumor embolization) within 2 weeks prior to the first dose of the study drug
Cannot have received: anti-tumor vaccine
Prior administration of an anti-tumor vaccine or live vaccine within 4 weeks prior to the first dose
Lab requirements
Blood counts
Hemoglobin ≥ 90 g/L (no blood transfusion within 14 days); ANC ≥ 1.5 × 10^9/L; Platelet count ≥ 90 × 10^9/L
Kidney function
Serum creatinine ≤ 1.5 × ULN
Liver function
Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN; for patients with liver metastases, ALT and AST ≤ 5 × ULN
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50%; QTc interval < 450 ms for males and < 470 ms for females
Adequate organ and bone marrow function, defined as: Hemoglobin ≥ 90 g/L (no blood transfusion within 14 days); ANC ≥ 1.5 × 10^9/L; Platelet count ≥ 90 × 10^9/L; Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN; for patients with liver metastases, ALT and AST ≤ 5 × ULN; Serum creatinine ≤ 1.5 × ULN; Left ventricular ejection fraction (LVEF) ≥ 50%; QTc interval < 450 ms for males and < 470 ms for females.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify